Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2

Detalhes bibliográficos
Ano de defesa: 2017
Autor(a) principal: Sartori, Gláubia da Silva
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
dARK ID: ark:/26339/001300000fsft
Idioma: por
Instituição de defesa: Universidade Federal de Santa Maria
Brasil
Bioquímica
UFSM
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
Centro de Ciências Naturais e Exatas
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
HSV
Link de acesso: http://repositorio.ufsm.br/handle/1/17976
Resumo: Infectious diseases caused by herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are among the pathologies that most affect the population. The search for new therapeutic alternatives for its treatment becomes relevant due to the growth of cases resistant to Aciclovir, a reference in the treatment of herpetic infections. Thus, this thesis investigated the effect of diphenyl diselenide (PhSe)2, an organic molecule of selenium, for the treatment of infections caused by herpes simplex virus 1 (HSV-1) and 2 (HSV-2) in vitro and in vivo. In the protocol 1 related to articles 1 and 2, the cell viability test (MTT) was initially performed to check the toxicity of the compound (1-100 μM) and later its effect on the virus was verified by the plaque reduction assay, both tests performed on VERO cell culture. After, the experiments were carried out in vivo. The protocol consisted of treatment with (PhSe)2 (5 mg/kg/day, intragastric, i.g.) 5 days before and 5 days after infection; mice were infected at day 6. The extravaginal lesion score was evaluated from days 6 to 10. At the end of treatments, the animals were killed and ex vivo analyses of the genital, renal, hepatic and plasma tissues were performed. Other parameters were also investigated such as viral load, histological analysis, oxidative stress, inflammation, immune response, antioxidant and anti-inflammatory enzyme activities, renal and hepatic toxicity parameters. In the protocol 2 related to the manuscript 1, the antiviral effect of (PhSe)2 against HSV-1 infection was investigated at different times post-infection (4 and 24 hours) in glial culture cells. The viral load was quantified through plaque reduction assay, inhibition of viral DNA synthesis and inhibition of genes involved in the replicative cycle (ICP27, ICP0, ICP8 and viral DNA polymerase). The activation of the immune system (NF-κB and TNF-α) in HSV-1 infected cells was also investigated. The results of articles 1 and 2 demonstrated an antiviral effect of (PhSe)2 in vitro and in vivo as well as the reduction of oxidative stress, inflammation and restoration of antioxidant capacity, such as the content of non-protein thiols and the activity of antioxidant enzymes. Furthermore, the compound protected against toxic effects generated by infection at the renal and hepatic levels. The results obtained in manuscript 1 were also positive because the antiviral effect of (PhSe)2 against HSV-1 infection in glial cells was confirmed as well as the reduction of viral DNA synthesis and regulation of the replicative cycle genes. The compound reduced the expression of most viral genes studied at different time points after infection. (PhSe)2 showed an immunomodulatory effect by reducing the expression of the cytokine TNF-α. From these data, (PhSe)2 can be considered an important therapeutic alternative to treat HSV-1 and HSV-2 infections.
id UFSM_c0669b1b364966d5ab214cdfe5d03b42
oai_identifier_str oai:repositorio.ufsm.br:1/17976
network_acronym_str UFSM
network_name_str Manancial - Repositório Digital da UFSM
repository_id_str
spelling Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2Diphenyl disselenide on viral infection models caused by herpes simplex viruses types 1 and 2HSVSelênioAntiviralEstresse oxidativoInflamaçãoCitocinasSeleniumAntiviralOxidative stressInflammationCytokinesCNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICAInfectious diseases caused by herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are among the pathologies that most affect the population. The search for new therapeutic alternatives for its treatment becomes relevant due to the growth of cases resistant to Aciclovir, a reference in the treatment of herpetic infections. Thus, this thesis investigated the effect of diphenyl diselenide (PhSe)2, an organic molecule of selenium, for the treatment of infections caused by herpes simplex virus 1 (HSV-1) and 2 (HSV-2) in vitro and in vivo. In the protocol 1 related to articles 1 and 2, the cell viability test (MTT) was initially performed to check the toxicity of the compound (1-100 μM) and later its effect on the virus was verified by the plaque reduction assay, both tests performed on VERO cell culture. After, the experiments were carried out in vivo. The protocol consisted of treatment with (PhSe)2 (5 mg/kg/day, intragastric, i.g.) 5 days before and 5 days after infection; mice were infected at day 6. The extravaginal lesion score was evaluated from days 6 to 10. At the end of treatments, the animals were killed and ex vivo analyses of the genital, renal, hepatic and plasma tissues were performed. Other parameters were also investigated such as viral load, histological analysis, oxidative stress, inflammation, immune response, antioxidant and anti-inflammatory enzyme activities, renal and hepatic toxicity parameters. In the protocol 2 related to the manuscript 1, the antiviral effect of (PhSe)2 against HSV-1 infection was investigated at different times post-infection (4 and 24 hours) in glial culture cells. The viral load was quantified through plaque reduction assay, inhibition of viral DNA synthesis and inhibition of genes involved in the replicative cycle (ICP27, ICP0, ICP8 and viral DNA polymerase). The activation of the immune system (NF-κB and TNF-α) in HSV-1 infected cells was also investigated. The results of articles 1 and 2 demonstrated an antiviral effect of (PhSe)2 in vitro and in vivo as well as the reduction of oxidative stress, inflammation and restoration of antioxidant capacity, such as the content of non-protein thiols and the activity of antioxidant enzymes. Furthermore, the compound protected against toxic effects generated by infection at the renal and hepatic levels. The results obtained in manuscript 1 were also positive because the antiviral effect of (PhSe)2 against HSV-1 infection in glial cells was confirmed as well as the reduction of viral DNA synthesis and regulation of the replicative cycle genes. The compound reduced the expression of most viral genes studied at different time points after infection. (PhSe)2 showed an immunomodulatory effect by reducing the expression of the cytokine TNF-α. From these data, (PhSe)2 can be considered an important therapeutic alternative to treat HSV-1 and HSV-2 infections.Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPESDoenças infecciosas ocasionadas pelo herpes simplex vírus do tipo 1 e 2 (HSV-1 e HSV-2) estão entre as patologias que mais acometem a população. A busca por novas alternativas terapêuticas para o seu tratamento torna-se relevante devido ao crescimento de casos resistentes ao Aciclovir, referência no tratamento de infecções herpéticas. Desta forma, esta tese investigou o efeito do disseleneto de difenila (PhSe)2, uma molécula orgânica de selênio, no tratamento de infecções geradas pelo herpes simplex vírus humano 1 (HSV-1) e 2 (HSV-2) in vitro e in vivo. No protocolo 1 referente aos artigos 1 e 2, foi realizado incialmente o teste de viabilidade celular (MTT) para verificar se há toxicidade do composto (1-100μM) e posteriormente verificou-se o seu efeito sobre o HSV-2 através do ensaio de redução de placa viral, ambos os testes realizados em cultura de células VERO. Após, foram realizados os experimentos in vivo. O protocolo consistiu de 5 dias de pré-tratamento com (PhSe)2 (5 mg/kg, via intragástrica, i.g.), infecção intravaginal no dia 6 e pós-tratamento com o composto por mais 5 dias. Ao final dos tratamentos, os animais foram mortos e análises ex vivo dos tecidos genital, renal, hepático e plasma foram realizadas. A evolução da lesão extravaginal foi analisada a cada dia pós-infecção. Outros parâmetros também foram investigados como carga viral, análise histológica, estresse oxidativo, inflamação, resposta imune, atividades de enzimas antioxidantes e anti-inflamatórias, parâmetros de toxicidade renal e hepática. No protocolo 2 referente ao manuscrito 1, as análises do efeito antiviral do (PhSe)2 contra a infecção por HSV-1 foram realizadas em dois tempos diferentes após a infecção (4 e 24 horas) em culturas de células gliais. Foi quantificada a carga viral através dos ensaios de redução de placa, inibição da síntese de DNA viral e inibição de genes envolvidos no ciclo replicativo (ICP27, ICP0, ICP8 e DNA polimerase viral). Também foi investigada a ativação do sistema imunológico (NF-κB e TNF-α) nas células infectadas por HSV-1. Os resultados referentes aos artigos 1 e 2 demonstraram um efeito antiviral do (PhSe)2 in vitro e in vivo bem como a redução do estresse oxidativo, inflamação, restauração da capacidade antioxidante como o conteúdo de tióis não-proteicos e da atividade de enzimas antioxidantes. Ainda, o composto protegeu contra efeitos tóxicos gerados pela infecção a nível renal e hepático. Os achados obtidos no manuscrito 1 também foram positivos, uma vez que foi confirmado o efeito antiviral do (PhSe)2 contra a infecção por HSV-1 nas células gliais bem como a redução da síntese de DNA viral e regulação dos genes do ciclo replicativo. O composto reduziu a expressão da maioria dos genes virais estudados nos diferentes tempos de análise após a infecção. E de certa forma apresentou efeito imunomodulador através da redução da expressão da citocina TNF-α. A partir dos dados obtidos pode-se considerar o (PhSe)2 uma importante alternativa terapêutica frente as infecções causadas pelo HSV-1 e HSV-2.Universidade Federal de Santa MariaBrasilBioquímicaUFSMPrograma de Pós-Graduação em Ciências Biológicas: Bioquímica ToxicológicaCentro de Ciências Naturais e ExatasNogueira, Cristina Waynehttp://lattes.cnpq.br/2877042401245169Prigol, Marinahttp://lattes.cnpq.br/6724052141066150Franco, Ana Claudiahttp://lattes.cnpq.br/6775292376712192Andrade, Cinthia Melazzo dehttp://lattes.cnpq.br/2886709251370905Simões, Cláudia Maria Oliveirahttp://lattes.cnpq.br/3613722593784448Schuch, André Passagliahttp://lattes.cnpq.br/4932611269622766Sartori, Gláubia da Silva2019-08-20T20:05:52Z2019-08-20T20:05:52Z2017-03-02info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisapplication/pdfhttp://repositorio.ufsm.br/handle/1/17976ark:/26339/001300000fsftporAttribution-NonCommercial-NoDerivatives 4.0 Internationalinfo:eu-repo/semantics/openAccessreponame:Manancial - Repositório Digital da UFSMinstname:Universidade Federal de Santa Maria (UFSM)instacron:UFSM2019-08-21T06:02:13Zoai:repositorio.ufsm.br:1/17976Biblioteca Digital de Teses e Dissertaçõeshttps://repositorio.ufsm.br/PUBhttps://repositorio.ufsm.br/oai/requestatendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.bropendoar:2019-08-21T06:02:13Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)false
dc.title.none.fl_str_mv Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2
Diphenyl disselenide on viral infection models caused by herpes simplex viruses types 1 and 2
title Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2
spellingShingle Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2
Sartori, Gláubia da Silva
HSV
Selênio
Antiviral
Estresse oxidativo
Inflamação
Citocinas
Selenium
Antiviral
Oxidative stress
Inflammation
Cytokines
CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA
title_short Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2
title_full Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2
title_fullStr Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2
title_full_unstemmed Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2
title_sort Disseleneto de difenila em modelos de infecção viral causada por herpes simplex vírus dos tipos 1 e 2
author Sartori, Gláubia da Silva
author_facet Sartori, Gláubia da Silva
author_role author
dc.contributor.none.fl_str_mv Nogueira, Cristina Wayne
http://lattes.cnpq.br/2877042401245169
Prigol, Marina
http://lattes.cnpq.br/6724052141066150
Franco, Ana Claudia
http://lattes.cnpq.br/6775292376712192
Andrade, Cinthia Melazzo de
http://lattes.cnpq.br/2886709251370905
Simões, Cláudia Maria Oliveira
http://lattes.cnpq.br/3613722593784448
Schuch, André Passaglia
http://lattes.cnpq.br/4932611269622766
dc.contributor.author.fl_str_mv Sartori, Gláubia da Silva
dc.subject.por.fl_str_mv HSV
Selênio
Antiviral
Estresse oxidativo
Inflamação
Citocinas
Selenium
Antiviral
Oxidative stress
Inflammation
Cytokines
CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA
topic HSV
Selênio
Antiviral
Estresse oxidativo
Inflamação
Citocinas
Selenium
Antiviral
Oxidative stress
Inflammation
Cytokines
CNPQ::CIENCIAS BIOLOGICAS::BIOQUIMICA
description Infectious diseases caused by herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) are among the pathologies that most affect the population. The search for new therapeutic alternatives for its treatment becomes relevant due to the growth of cases resistant to Aciclovir, a reference in the treatment of herpetic infections. Thus, this thesis investigated the effect of diphenyl diselenide (PhSe)2, an organic molecule of selenium, for the treatment of infections caused by herpes simplex virus 1 (HSV-1) and 2 (HSV-2) in vitro and in vivo. In the protocol 1 related to articles 1 and 2, the cell viability test (MTT) was initially performed to check the toxicity of the compound (1-100 μM) and later its effect on the virus was verified by the plaque reduction assay, both tests performed on VERO cell culture. After, the experiments were carried out in vivo. The protocol consisted of treatment with (PhSe)2 (5 mg/kg/day, intragastric, i.g.) 5 days before and 5 days after infection; mice were infected at day 6. The extravaginal lesion score was evaluated from days 6 to 10. At the end of treatments, the animals were killed and ex vivo analyses of the genital, renal, hepatic and plasma tissues were performed. Other parameters were also investigated such as viral load, histological analysis, oxidative stress, inflammation, immune response, antioxidant and anti-inflammatory enzyme activities, renal and hepatic toxicity parameters. In the protocol 2 related to the manuscript 1, the antiviral effect of (PhSe)2 against HSV-1 infection was investigated at different times post-infection (4 and 24 hours) in glial culture cells. The viral load was quantified through plaque reduction assay, inhibition of viral DNA synthesis and inhibition of genes involved in the replicative cycle (ICP27, ICP0, ICP8 and viral DNA polymerase). The activation of the immune system (NF-κB and TNF-α) in HSV-1 infected cells was also investigated. The results of articles 1 and 2 demonstrated an antiviral effect of (PhSe)2 in vitro and in vivo as well as the reduction of oxidative stress, inflammation and restoration of antioxidant capacity, such as the content of non-protein thiols and the activity of antioxidant enzymes. Furthermore, the compound protected against toxic effects generated by infection at the renal and hepatic levels. The results obtained in manuscript 1 were also positive because the antiviral effect of (PhSe)2 against HSV-1 infection in glial cells was confirmed as well as the reduction of viral DNA synthesis and regulation of the replicative cycle genes. The compound reduced the expression of most viral genes studied at different time points after infection. (PhSe)2 showed an immunomodulatory effect by reducing the expression of the cytokine TNF-α. From these data, (PhSe)2 can be considered an important therapeutic alternative to treat HSV-1 and HSV-2 infections.
publishDate 2017
dc.date.none.fl_str_mv 2017-03-02
2019-08-20T20:05:52Z
2019-08-20T20:05:52Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://repositorio.ufsm.br/handle/1/17976
dc.identifier.dark.fl_str_mv ark:/26339/001300000fsft
url http://repositorio.ufsm.br/handle/1/17976
identifier_str_mv ark:/26339/001300000fsft
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Bioquímica
UFSM
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
Centro de Ciências Naturais e Exatas
publisher.none.fl_str_mv Universidade Federal de Santa Maria
Brasil
Bioquímica
UFSM
Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica
Centro de Ciências Naturais e Exatas
dc.source.none.fl_str_mv reponame:Manancial - Repositório Digital da UFSM
instname:Universidade Federal de Santa Maria (UFSM)
instacron:UFSM
instname_str Universidade Federal de Santa Maria (UFSM)
instacron_str UFSM
institution UFSM
reponame_str Manancial - Repositório Digital da UFSM
collection Manancial - Repositório Digital da UFSM
repository.name.fl_str_mv Manancial - Repositório Digital da UFSM - Universidade Federal de Santa Maria (UFSM)
repository.mail.fl_str_mv atendimento.sib@ufsm.br||tedebc@gmail.com||manancial@ufsm.br
_version_ 1847153393813946368